Accretion Pharmaceuticals Limited
Accretion Pharmaceuticals Limited is a pharmaceutical CDMO engaged in the manufacturing and marketing of a wide range of formulations including tablets, capsules, oral liquids, external preparations, and oral powders. The company operates through domestic sales, direct exports, and merchant exporter arrangements, with its products being supplied to several international markets through direct and indirect channels. With a strong focus on quality and compliance, the company caters to diverse client needs across geographies. Its operations are supported by a modern manufacturing facility and a dedicated team committed to excellence.
Price Band₹96 - ₹101 |
Dates14 May - 16 May |
GMP₹0 (0.00%) |
Subscriptions7.15 times |
Issue Size₹29.75 Crs |
Accretion Pharmaceuticals IPO Objects
- Capital expenditure towards purchase of new equipment / machineries
- Capital expenditure towards upgradation of existing manufacturing facility
- Repayment of certain borrowings availed by our Company
- Funding working capital requirements
- General Corporate Purpose
Accretion Pharmaceuticals IPO Details
Price Band₹96 - ₹101 |
Listing AtNSE SME |
IPO Issue Type100% Book Built Offer |
Fresh Issue₹29.75 Cr (0.29 Cr Shares) |
Offer For Sale₹0.00 (0.00 Shares) |
Total Issue₹29.75 Cr (0.29 Cr Shares) |
Face Value₹10 per equity share |
Accretion Pharmaceuticals IPO Lot Information
| Investor Category | Lot | Shares | Amount | |
|---|---|---|---|---|
| Retail |
Minimum
1
1,200
1,21,200
Maximum
1
1,200
1,21,200
|
|||
| NII |
Minimum
2
2,400
2,42,400
|
|||
Accretion Pharmaceuticals IPO Subscription
Updated as on 16-May-2025 19:00:05 hrs
| Investor Category | Subscription (times) | Shares Offered | Shared Bid |
|---|---|---|---|
| QIB | 4.87 | 3,52,800 | 17,19,600 |
| NII | 4.41 | 12,22,800 | 53,91,600 |
| Retail | 10.55 | 12,22,800 | 1,28,95,200 |
| Total | 7.15 | 27,98,400 | 2,00,06,400 |
Accretion Pharmaceuticals IPO GMP
The estimated Grey Market Premium of Accretion Pharmaceuticals IPO is ₹0 per share (0.00%)
Disclaimer: The GMP prices displayed here reflect news related to grey market trends. We do not trade or deal in the grey market, including subject-to-rates, nor do we recommend participating in grey market trading.
Category Allocation
| Particulars | Allocation |
|---|---|
| QIB | Not more than 50% of Net Offer |
| NII | Not less than 15% of Net Offer |
| Retail | Not less than 35% of Net Offer |
| Market Maker | 1,47,600 EQ Shares |
Accretion Pharmaceuticals IPO Financials
| Particulars | Dec-24 | Mar-24 | Mar-23 | Mar-22 |
|---|---|---|---|---|
| Revenue from Operations | 35.67 | 33.67 | 29.38 | 22.29 |
| Profit after Tax | 5.24 | 3.88 | 0.10 | 0.08 |
| Net Worth | 13.58 | 5.35 | 3.84 | 3.08 |
| Total Borrowing | 13.79 | 13.48 | 8.47 | 7.61 |
| Total Assets | 39.99 | 27.05 | 20.58 | 17.74 |
| NAV per share (in ₹) | 17.09 | 13.37 | NA | NA |
| EPS - Basic (in ₹) | 8.74 | 9.69 | NA | NA |
The financial information presented is on a consolidated basis.
Key Performance Indicators
| KPI | KPI |
|---|---|
| EBITDA | 23.06% |
| PAT | 11.51% |
| ROE | 72.80% |
| ROCE | 36.73% |
| PE Ratio | 10.42 |
| PB Ratio | 7.55 |
| Mkt Cap (in Crs.) | 112.27 |
- All Ratios are based on Mar 24
- PE, PB, and Post-Issue Market Capitalization are calculated based on the upper price band.
Accretion Pharmaceuticals IPO Peer Comparision
| Particulars | Accretion Pharma | Sakar Healthcare | Lincoln Pharmaceuticals | Sotac Pharmaceuticals |
|---|---|---|---|---|
| Revenue from Ops (in Crs.) | 33.67 | 153.35 | 580.55 | 67.11 |
| PAT (In Crs.) | 3.88 | 11.67 | 93.30 | 5.75 |
| EPS - Basic | 9.69 | 5.64 | 46.58 | 5.24 |
| NAV per share | 13.37 | 120.65 | 295.98 | 43.69 |
| RONW | 72.80% | 4.45% | 15.74% | 11.91% |
| EBITDA | 23.06% | 26.47% | 23.14% | 17.16% |
| Price to earning (PE) | 10.42 | 48.89 | 12.30 | 23.85 |
- All the information pertains to FY 2023-24
- The PE ratio is calculated using the Upper Price Band for the Issuer and the closing price as of May 05, 2025 for Peers
Accretion Pharmaceuticals IPO Peer Comparision
| Particulars | Accretion Pharma |
|---|---|
| Revenue from Ops (in Crs.) | 33.67 |
| PAT (In Crs.) | 3.88 |
| EPS - Basic | 9.69 |
| NAV per share | 13.37 |
| RONW | 72.80% |
| EBITDA | 23.06% |
| Price to earning (PE) | 10.42 |
| Sakar Healthcare | Lincoln Pharmaceuticals | Sotac Pharmaceuticals |
|---|---|---|
| 153.35 | 580.55 | 67.11 |
| 11.67 | 93.30 | 5.75 |
| 5.64 | 46.58 | 5.24 |
| 120.65 | 295.98 | 43.69 |
| 4.45% | 15.74% | 11.91% |
| 26.47% | 23.14% | 17.16% |
| 48.89 | 12.30 | 23.85 |
- All the information pertains to FY 2023-24
- The PE ratio is calculated using the Upper Price Band for the Issuer and the closing price as of May 05, 2025 for Peers
Promoter Details
| Name | Shareholding |
|---|---|
| Mayur Popatlal Sojitra | 24.07% |
| HarshadNanubhaiRathod | 24.07% |
| Vivek Ashok Kumar Patel | 24.07% |
| Hardik Mukundbhai Prajapati | 24.07% |
| Others Promoter | 3.72% |
Management Details
| Name | Designation |
|---|---|
| Vivek Ashok Kumar Patel | MD |
| Harshad Nanubhai Rathod | CFO |
Company Details
Name: Accretion Pharmaceuticals Limited
Address: 29 Xcelon Ind Park 1, B/h, Intas Pharmaceuticals, Vasna Chacharvadi, Ahmedabad, Sanand, Gujarat, India, 382213
Number: +91-97148 82929
Email: compliance@accretionpharma.com
Website: http://www.accretionp harma.com
Book Running Lead Managers (BRLMs)
Jawa Capital
Visit WebsiteRTAs
KFin Technologies
Visit WebsiteFrequently Asked questions?
Find answers to common questions that come in your mind related to IPO.
Accretion Pharmaceuticals IPO is a SME IPO having an issue size of Rs. ₹29.75 Crs. Accretion Pharmaceuticals IPO is priced at ₹96 - ₹101 per share. The issue opens on 14 May 25 and closes on 16 May 25.
Accretion Pharmaceuticals IPO opens on 14 May 25 and closes on 16 May 25.
The estimated Grey Market Premium of Accretion Pharmaceuticals IPO is ₹0 per share (0.00%).
The minimum lot size of Accretion Pharmaceuticals IPO is 1200 shares & the minimum application amount is Rs. 121200.
The allotment date of Accretion Pharmaceuticals IPO is 19 May 25.
The listing date of Accretion Pharmaceuticals IPO is 21 May 25.
Accretion Pharmaceuticals IPO is subscribed 7.15 times.
Accretion Pharmaceuticals IPO is priced at ₹96 - ₹101 per share.
Click the allotment link on Accretion Pharmaceuticals IPO page of IPO360.
- Go to Kite App → Tap on Bids → Tap on IPO
- Select the IPO → Tap on apply → Enter UPI ID
- Enter Qty and Price
- Submit the application
- Approve the UPI Mandate on your UPI app
- Go to Groww App → Stocks Section → Select IPO option
- Select the IPO you want to apply
- Enter your bid details and price
- Enter UPI ID & submit
- Approve the UPI Mandate on your UPI app
- Log in to your bank's net banking portal.
- Navigate to the 'IPO' or 'ASBA' section.
- Select Accretion Pharmaceuticals IPO from the list of available IPOs.
- Enter the required details: Bid quantity, Price, DP ID & Client ID, etc
- Submit the application.
- Money will remain blocked till the refund date
We are a one-stop destination for all your IPO needs. Get reliable, accurate, and timely information for all the IPOs in India!